bisoprolol / Generic mfg. - LARVOL DELTA

Atenolol or Bisoprolol after Myocardial Infarction without Recorded Heart Failure. (PubMed, NEJM Evid) - "Among patients without recorded characteristics in an administrative database suggesting the presence of heart failure, initiation of atenolol after myocardial infarction was associated with a lower risk of major adverse cardiovascular events, but not all-cause mortality, at 2 years compared with bisoprolol. (Funded by PRAIRIE and others.)."

Journal • Observational data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Comprehensive Spectroscopic, Computational, and Pharmacokinetic Characterization of the Cardiovascular Drug- Bisoprolol. (PubMed, Curr Med Chem) - "Based on the in silico molecular docking investigations and ADME predictions, it is reasonable to conclude that the metabolic pathways of bisoprolol and its interactions with biological systems are highly likely to be consistent with the available literature."

Journal • PK/PD data • Cardiovascular • Hypertension

Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review. (PubMed, Am J Cardiovasc Drugs) - "In adrenergically mediated inherited syndromes, namely catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, nonselective agents and especially nadolol are clearly superior to beta1-selective agents, and the same principle appears to extend to ventricular electrical storm, in which propranolol has outperformed metoprolol in a randomized comparison. In acute care, pharmacokinetics dominate, and the ultra-short-acting agents esmolol and landiolol permit a degree of titration that longer-acting drugs cannot match. In patients with heart failure and reduced ejection fraction, carvedilol, metoprolol succinate, and bisoprolol should be preferred irrespective of arrhythmia subtype because of their established mortality benefit. Conversely, beta1-selective agents, including the highly selective agent nebivolol, improve tolerability in bronchospastic disease, although this reflects respiratory tolerability rather than any demonstrated antiarrhythmic..."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Ventricular Tachycardia

Bisoprolol prophylaxis reduces supraventricular arrhythmias after lung transplantation: a retrospective cohort study (ERS 2026) - "No differences were observed in survival or chronic lung allograft dysfunction (CLAD). Prophylactic bisoprolol in the early post-lung transplant period was associated with a significant reduction in supraventricular arrhythmias without relevant safety concerns."

Retrospective data • Atrial Fibrillation • Cardiovascular • Respiratory Diseases • Transplantation

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

COMPARING METOPROLOL AND BISOPROLOL IN SYSTOLIC HEART FAILURE WITH ORTHOSTATIC HYPOTENSION: A REAL-WORLD STUDY (CHEST 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

BRAVE-HCM: The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction (clinicaltrials.gov) - P4 | N=132 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting ➔ Enrolling by invitation | Trial primary completion date: Jul 2026 ➔ Nov 2026

Enrollment open • Real-world evidence • Trial primary completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Real-world analysis of adherence, persistence, and outcomes in patients receiving four-drug antihypertensive therapy. (PubMed, Eur Heart J Cardiovasc Pharmacother) - "In patients receiving four-drug antihypertensive therapy, adherence and persistence were significantly improved with lower pill burden. Persistence was associated with lower risks of CVE and mortality."

Journal • Real-world evidence • Cardiovascular • Hypertension

Microaxial Flow Pump and Ivabradine for Tachycardia-Induced Cardiogenic Shock Caused by Automatic Atrial Tachycardia. (PubMed, JACC Case Rep) - "A microaxial flow pump may provide hemodynamic support, facilitating safe rate control and myocardial recovery in TIC complicated by cardiogenic shock. Ivabradine may be useful when beta-blockers are difficult to initiate."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure

Drugs associated with retroperitoneal fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database. (PubMed, Pharmacol Rep) - "This pharmacovigilance analysis identified multiple medications, spanning different therapeutic classes, that demonstrated a disproportionate association with reports of RPF. Notably, some drugs with well-established safety profiles also emerged as potential signals, warranting increased clinical awareness. While this analysis reveals pharmacovigilance signals suggestive of drug-induced RPF, the observational nature of FAERS data limits causal inference. These findings underscore the need for further clinical research and mechanistic studies to better understand the etiopathogenic role of these agents in RPF development."

Adverse events • Journal • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

Elevated sympathetic tone exacerbates myocardial ischemia reperfusion injury through enhancing endothelial cell inflammation and apoptosis in chronic pain mice. (PubMed, Clin Sci (Lond)) - "Finally, bisoprolol not only reduced heart rate, but also decreased myocardial infarction, inhibited endothelial cell apoptosis and NLRP3 expression. In conclusion, sympathetic nerve-driven endothelial apoptosis and inflammation were key pathological processes through which chronic pain exacerbated MI/R injury. The sympathetic-NLRP3 pathway contributed at least in part to the phenotype, with endothelial cells as an important but not exclusive target. Although the current data were obtained exclusively from young male mice, these findings establish a conserved mechanistic framework that warrants validation in female, aged, and clinically relevant models."

Journal • Preclinical • Cardiovascular • Inflammation • Myocardial Infarction • Myocardial Ischemia • Pain • Reperfusion Injury • FOS • NLRP3

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Headache) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Neurology) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • Review • CNS Disorders • Migraine • Pain

Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial. (PubMed, ESMO Open) - "Ramipril and bisoprolol significantly reduce the incidence of subclinical cardiac damage in patients with breast cancer undergoing anthracycline-based chemotherapy, thus supporting their use as early prevention cardioprotective strategies."

Journal • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Advanced Bisoprolol Oral Liquid Formulations for Flexible Pediatric and Geriatric Pharmacotherapy. (PubMed, AAPS PharmSciTech) - "Microbiological quality and palatability were maintained throughout the study. These findings demonstrate that the strategy based on QbD principles enables the development of robust, patient-centric OLFs, representing a reliable alternative to extemporaneous preparations and supporting safer, more flexible cardiovascular therapy."

Journal • Cardiovascular • Geriatric Disorders • Pediatrics

Recurrent Episodes of New-Onset Supraventricular Tachycardia in Severe Early-Onset Pre-eclampsia and Fetal Growth Restriction: A Report of a Complex Cardio-Obstetric Case. (PubMed, Cureus) - "She was subsequently stabilised on bisoprolol and enalapril, with no further documented SVT episodes before discharge. Furthermore, it demonstrates that delivery is not always the definitive solution to complex obstetric pathology, as significant maternal cardiovascular morbidity may persist beyond the immediate postpartum period. Finally, the case emphasises the importance of listening to maternal concerns regarding fetal well-being, even when initial assessments are reassuring, and recognising the need for ongoing psychological support and counselling following traumatic pregnancy complications."

Journal • Anesthesia • Cardiovascular • Critical care • Gynecology • Hypertension • Obstetrics • Ventricular Tachycardia

Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study. (PubMed, Pharmaceuticals (Basel)) - "Objective: We investigated the association between selected BBs and metabolic diseases using a large pharmacovigilance database and compared the reporting profiles of metoprolol (MET), carvedilol (CAR), bisoprolol (BIS), and nebivolol (NEB). MET and to a lesser extent CAR were associated with higher reporting odds of metabolic diseases, whereas BIS and especially NEB demonstrated more favorable reporting profiles. Although causality cannot be established from spontaneous reporting data, these findings support individualized BB selection and closer metabolic monitoring in patients with cardiometabolic risk factors."

Adverse events • Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Comparative clinical outcomes of nebivolol versus bisoprolol in patients with STEMI after primary PCI: a propensity-score matched analysis (ESC 2026) - "Among patients with STEMI treated with primary PCI, nebivolol and bisoprolol were associated with comparable clinical outcomes."

Clinical • Clinical data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Thrombosis

Apical Hypertrophic Cardiomyopathy Mimicking Wellens Syndrome: A Diagnostic Challenge in a Patient Presenting With Recurrent Angina. (PubMed, Cureus) - "Treatment with bisoprolol, telmisartan, and atorvastatin resulted in complete symptom resolution, and the patient remained asymptomatic during follow-up. This case highlights the importance of considering ApHCM in the differential diagnosis of patients presenting with giant T-wave inversion and suspected acute coronary syndrome, as recognition of its characteristic electrocardiographic and echocardiographic features can facilitate an accurate diagnosis and help avoid misinterpreting Wellens-like electrocardiographic patterns as true Wellens syndrome."

Journal • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Diabetes • Hypertension • Hypertrophic Cardiomyopathy • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus

Comparative clinical outcomes of carvedilol versus bisoprolol in STEMI survivors after primary PCI: a propensity-score matched analysis (ESC 2026) - "In STEMI survivors treated with contemporary primary PCI, carvedilol and bisoprolol demonstrated comparable 3-year clinical outcomes. This prognostic parity allows clinicians to individualize beta-blocker selection without compromising long-term survival or ischemic protection."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Metoprolol versus bisoprolol in patients with acute myocardial infarction: a target trial emulation study (ESC 2026) - "In this target trial emulation of AMI patients, bisoprolol was associated with higher all-cause and cardiovascular mortality compared with metoprolol, with a dose-dependent relationship."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Pharmacological modulation of cardiac senescence reveals divergent transcriptomic reversal patterns in human cardiomyocytes (ESC 2026) - "Senescent cardiomyocytes were exposed to eight compounds (dasatinib, quercetin, rapamycin, metformin, bisoprolol, insulin, IGF-1, and glucagon) at three concentrations...Large transcriptomic shifts do not necessarily indicate reversal of senescence, whereas directionally coherent changes may occur with modest DEG burdens. Directionality-aware transcriptomic scoring provides a scalable framework for prioritising candidate cardiometabolic and geroprotective interventions targeting cardiac ageing."

Cardiovascular • IGF1

Beta‑blocker tapering and symptom improvement in dysautonomic dysfunction patients (ESC 2026) - "Cardioselective beta‑blockers were commonly used (metoprolol succinate 33 %, metoprolol tartrate 29 %, bisoprolol 28 %, carvedilol 11 %). Symptom improvements were observed across the full spectrum of dose reduction; this highlights the synergistic value of combining beta‑blocker tapering with multimodal rehabilitation. Prospective controlled studies are warranted to confirm these observations and to optimise pharmacological strategies in dysautonomic dysfunction management."

Clinical • Cardiovascular

Chronotropic incompetence and negative chronotropic therapy in myocardial infarction patients during Phase 2 Cardiac Rehabilitation (ESC 2026) - "NCT was recorded in absolute and equivalent doses standardized to bisoprolol 2.5mg units (B2.5EU)...Deprescription of NCT is associated with the most pronounced improvement in chronotropic response after Phase 2 CRP. The role of this strategy in post-MI patients with CI and no clear indication for NCT warrants further investigation."

Clinical • P2 data • Cardiovascular • Myocardial Infarction

Long-term effect of beta-blockers after myocardial infarction with preserved left ventricular ejection fraction in a per protocol analysis of the REDUCE-AMI trial (ESC 2026) - "All dispensation data relating to the beta-blockers metoprolol succinate and bisoprolol (the treatment strategies defined in the trial protocol) were manually extracted. The study population was composed of 4,786 individuals. The median follow up was 30 months in the beta-blocker group and 38 months in the no beta-blocker group. Adherence was 71.8% in the beta-blocker group, and 89.7% in the no beta-blocker group."

Clinical • Cardiovascular • Myocardial Infarction